The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Abstract
CONTEXT: The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation. OBJECTIVE: To assess efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion SR) and placebo. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, parallel-group, placebo- and active-treatment-controlled, phase 3 clinical trial conducted at 19 US centers from June 19, 2003, to April 22, 2005. Participants were 1025 generally healthy smokers (> or =10 cigarettes/d) with fewer than 3 months of smoking abstinence in the past year, 18 to 75 years old, recruited via advertising. INTERVENTION: Participants were randomly assigned in a 1:1:1 ratio to receive brief counseling and varenicline titrated to 1 mg twice per day (n = 352), bupropion SR titrated to 150 mg twice per day (n = 329), or placebo (n = 344) orally for 12 weeks, with 40 weeks of nondrug follow-up. MAIN OUTCOME MEASURES: Primary outcome was the exhaled carbon monoxide-confirmed 4-week rate of continuous abstinence from smoking for weeks 9 through 12. A secondary outcome was the continuous abstinence rate for weeks 9 through 24 and weeks 9 through 52. RESULTS: For weeks 9 through 12, the 4-week continuous abstinence rates were 44.0% for varenicline vs 17.7% for placebo (odds ratio [OR], 3.85; 95% confidence interval [CI], 2.70-5.50; P<.001) and vs 29.5% for bupropion SR (OR, 1.93; 95% CI, 1.40-2.68; P<.001). Bupropion SR was also significantly more efficacious than placebo (OR, 2.00; 95% CI, 1.38-2.89; P<.001). For weeks 9 through 52, the continuous abstinence rates were 21.9% for varenicline vs 8.4% for placebo (OR, 3.09; 95% CI, 1.95-4.91; P<.001) and vs 16.1% for bupropion SR (OR, 1.46; 95% CI, 0.99-2.17; P = .057). Varenicline reduced craving and withdrawal and, for those who smoked while receiving study drug, smoking satisfaction. No sex differences in efficacy for varenicline were observed. Varenicline was safe and generally well tolerated, with study drug discontinuation rates similar to those for placebo. The most common adverse events for participants receiving active-drug treatment were nausea (98 participants receiving varenicline [28.1%]) and insomnia (72 receiving bupropion SR [21.9%]). CONCLUSION: Varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficacious than bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00141206.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, is reported to increase continuous abstinence rates to ∼50% following 12 weeks of treatment, which is significantly better than bupropion (∼30%) or placebo (∼18%”
From Parallel Anxiolytic-Like Effects and Upregulation of Neuronal Nicotinic Acetylcholine Receptors Following Chronic Nicotine and Varenicline (2011) · cites this paper as Gonzales et al., 2006
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“These trials document treatment-related reductions in smoking urges and withdrawal-related negative affect (4, 5, 9), as well as reduced smoking reward during a lapse (10).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“The effects of varenicline on subjective abstinence symptoms were of a magnitude similar to those observed in clinical efficacy trials (4, 36).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“Individuals who relapsed derived less enjoyment from smoking while taking varenicline [241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Nearly one quarter (21–23%) of patients taking varenicline for a short period of time (12 weeks) maintained abstinence at 52 weeks of follow-up.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Gonzales and colleagues [241] found a similar decrease in negative affect, but also found a significant decrease in restlessness in patients taking varenicline.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“This represents a significant improvement over sustained-release bupropion (14–16%) and placebo (8–10%).”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Two large, randomized, placebo-controlled studies released in 2006 related the efficacy of varenicline to that of bupropion in aided smoking cessation [233, 241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“numerous studies have shown that varenicline, a Food and Drug Administration-approved drug widely used to help people quit smoking, potently acts as a partial agonist at ␣42* nAChRs”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Gonzales et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Cigarette Smoking Among Adults--United States, 2003
(2005) · JAMA · doi:10.1001/jama.294.2.172 · Cited by 1,520
Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Fiore, M. (2000) · Respiratory care · doi:10.1177/002013240004501006 · Cited by 773
Cited by
Sorted by citations
Items 701–800 of 1,000
A Thoracic Surgeon–Directed Tobacco Cessation Intervention
Kozower, B. D., Lau, C. L., Phillips, J. V., Burks, S. G., Jones, D. R., & Stukenborg, G. J. (2010) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2009.12.046 · Cited by 16
Nicotine dependence as a moderator of a quitline-based message framing intervention
Fucito, L. M., Latimer‐Cheung, A. E., Carlin-Menter, S. M., Salovey, P., Cummings, K. M., Makuch, R., & Toll, B. A. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.09.012 · Cited by 16
Horn, L., Eisenberg, R., Gius, D. R., Kimmelshue, K. N., Massion, P. P., Putnam, J. B., Robinson, C. G., & Carbone, D. P. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00072-2 · Cited by 16
Doggrell, S. A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.17.2903 · Cited by 16
Koga, M., Kanaoka, Y., Ohkido, Y., Kubo, N., Ohishi, K., Sugiyama, K., Yamauchi, A., & Kataoka, Y. (2014) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2014.10.150 · Cited by 17
Varenicline for E-Cigarette Cessation in Adults: A Preliminary Placebo-Controlled Randomized Trial
Fucito, L. M., Baldassarri, S. R., Baker, N. L., Palmer, A. M., O’Malley, S. S., Carpenter, M. J., Krishnan‐Sarin, S., Gray, K. M., & Toll, B. A. (2024) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2024.04.007 · Cited by 15
Cohen, G. A., Bellanca, C. M., Bernardini, R., Rose, J. E., & Polosa, R. (2024) · iScience · doi:10.1016/j.isci.2024.111090 · Cited by 15
Influence of smoking abstinence and nicotine replacement therapy on heart rate and QT time‐series
Lewis, M. J., Balaji, G., Dixon, H., Syed, Y., & Lewis, K. E. (2009) · Clinical Physiology and Functional Imaging · doi:10.1111/j.1475-097x.2009.00902.x · Cited by 15
Parikh, V., Cole, R. D., Patel, P., Poole, R. L., & Gould, T. J. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.01.003 · Cited by 15
Ravva, P., Gastonguay, M. R., Faessel, H. M., Lee, T. C., & NIAURA, R. S. (2014) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntu154 · Cited by 16
Shen, Z., Huang, P., Wang, C., Qian, W. P., Yang, Y., & Zhang, M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.02.002 · Cited by 15
Baldwin, A. S., Rothman, A. J., Hertel, A. W., Keenan, N. K., & Jeffery, R. W. (2008) · Psychology and Health · doi:10.1080/08870440701639377 · Cited by 15
Carson‐Chahhoud, K., Smith, B. J., Brinn, M. P., Peters, M. J., Fitridge, R., Koblar, S. A., Jannes, J., Singh, K., Veale, A., Goldsworthy, S. J., et al. (2014) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntu112 · Cited by 15
Pharmacokinetics of cytisine after single intravenous and oral administration in rabbits
Astroug, H. A., Simeonova, R., Kassabova, L., Danchev, N., & Svinarov, D. A. (2010) · Interdisciplinary Toxicology · doi:10.2478/v10102-010-0003-5 · Cited by 15
Kim, Y., Kornfield, R., Shi, Y., Vera, L., Daubresse, M., Alexander, G. C., & Emery, S. (2015) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntv198 · Cited by 15
Varenicline and Abnormal Sleep Related Events
Savage, R. L., Zekarias, A., & Caduff‐Janosa, P. (2015) · SLEEP · doi:10.5665/sleep.4686 · Cited by 15
Benowitz, N. L., & Brunetta, P. G. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00046-4 · Cited by 15
George, T. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00031-2 · Cited by 15
Carney, G., Bassett, K. L., Maclure, M., Taylor, S., & Dormuth, C. R. (2020) · Addiction · doi:10.1111/add.14951 · Cited by 15
Rimonabant for treating tobacco dependence.
Steinberg, M. B., & Foulds, J. (2007) · PubMed Central · Cited by 15
Caring for the smoking asthmatic patient
Polosa, R., Caponnetto, P., & Sands, M. F. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.015 · Cited by 15
Schnoll, R. A., Cappella, J. N., Lerman, C. E., Pinto, A. G., Patterson, F., Wileyto, E. P., Bigman, C. A., & Leone, F. T. (2011) · Health Communication · doi:10.1080/10410236.2011.566829 · Cited by 15
Association of Out-of-Pocket Pharmacy Costs with Adherence to Varenicline
Suehs, B. T., Davis, C. D., Galaznik, A., Joshi, A. V., Zou, K. H., & Patel, N. C. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.6.592 · Cited by 15
Slyepchenko, A., Brunoni, A. R., McIntyre, R. S., Quevedo, J., & Carvalho, A. F. (2016) · Current Molecular Medicine · doi:10.2174/1566524016666160126144601 · Cited by 14
von Wartburg, M., Raymond, V., & Paradis, P. E. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12363 · Cited by 14
Evins, A. E., Pachas, G. N., Mischoulon, D., Urbanoski, K. A., Carlini, S. V., Sousa, J., Bentley, K. H., Rigotti, N. A., Nino, J., Loebl, T., et al. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822bb390 · Cited by 14
Consenso sobre la atención sanitaria del tabaquismo en España
Guillem, F. C., Llivina, T. S., Torell, J. M. R., García, R. C., Ruiz, C. J., García-Aranda, V. L., Villalbí, J. R., Santos, M. Á. P., Monfort, J. S., & Santiago, A. L. (2009) · Revista Española de Salud Pública · doi:10.1590/s1135-57272009000200004 · Cited by 15
Zhu, S., Cummins, S. E., Gamst, A. C., Wong, S., & Ikeda, T. (2015) · Tobacco Control · doi:10.1136/tobaccocontrol-2015-052332 · Cited by 14
NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
Ettinger, D. S., Kimmel, S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., Jahan, T. M., et al. (2014) · Cited by 14
Safety of Varenicline for Smoking Cessation in Psychiatric and Addicts Patients
Raich, A., Ballbè, M., Nieva, G., Cano, M., Fernández, T., Bruguera, E., & Fernández, E. (2016) · Substance Use & Misuse · doi:10.3109/10826084.2015.1133646 · Cited by 15
Hamouda, A. K., Jackson, A. B., Bağdaş, D., & Damaj, M. I. (2017) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntx183 · Cited by 14
Versace, F., Stevens, E. M., Robinson, J. D., Cui, Y., Deweese, M. M., Engelmann, J. M., Green, C. E., Karam‐Hage, M., Lam, C. Y., Minnix, J. A., et al. (2017) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntx264 · Cited by 14
Varenicline for long term smoking cessation in patients with COPD
Zenteno, R. H., Lara, D. F., Venegas, A. R., Sansores, R. H., Pineda, J. R., Flores-Trujillo, F., Padilla, J. R. P., Matera, M. G., & Cazzola, M. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.11.001 · Cited by 14
Quinn, M. H., Bauer, A., Flitter, A., Lubitz, S. F., Ashare, R. L., Thompson, M., Leone, F. T., Gross, R., & Schnoll, R. A. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.106151 · Cited by 14
Zhang, H., Mansoursadeghi-Gilan, T., Hussain, S., Veldhuizen, S., Foll, B. L., Selby, P. L., & Zawertailo, L. A. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109312 · Cited by 14
Dunn, K. E., Saulsgiver, K. A., & Sigmon, S. C. (2011) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0022039 · Cited by 16
Hughes, J. R., Russ, C., Arteaga, C. E. Q., & Rennard, S. I. (2011) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.08.001 · Cited by 14
Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers
Yardley, M. M., Mirbaba, M., & Ray, L. A. (2015) · CNS Drugs · doi:10.1007/s40263-015-0284-5 · Cited by 15
Daley, C. M., Daley, S. M., Pacheco, C. M., Smith, T. E., Talawyma, M., McCloskey, C., Choi, W. S., Nazir, N., Filippi, M. K., McKinney, D., et al. (2017) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntx030 · Cited by 14
Koga, M., Kanaoka, Y., Okamoto, M., Nakao, Y., Inada, K., Takayama, S., Kataoka, Y., & Yamauchi, A. (2019) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2019.11.002 · Cited by 14
Selby, P. L., Hussain, S., Voci, S. C., & Zawertailo, L. A. (2015) · Implementation Science · doi:10.1186/s13012-015-0329-7 · Cited by 14
Polyethylene glycol-based homologated ligands for nicotinic acetylcholine receptors
Scates, B. A., Lashbrook, B. L., Chastain, B. C., Tominaga, K., Elliott, B. T., Theising, N. J., Baker, T. A., & Fitch, R. W. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.045 · Cited by 14
Varenicline: progress in smoking cessation treatment
Glover, E. D., & Rath, J. M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1757 · Cited by 14
Cesa, L. C., Higgins, C. A., Sando, S. R., Kuo, D. W., & Levandoski, M. M. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.076059 · Cited by 14
▼Varenicline for smoking cessation
BMJ Publishing Group Ltd (2008) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2008.04.0010 · Cited by 14
Pezzuto, A., D’Ascanio, M., Grieco, A., & Rícci, A. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.07.032 · Cited by 14
Daumit, G. L., Evins, A. E., Cather, C., Dalcin, A. T., Dickerson, F. B., Miller, E. R., Appel, L. J., Jerome, G. J., McCann, U., Ford, D. E., et al. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.1691 · Cited by 13
Mazoni, C. G., Fernandes, S., Pierozan, P. S., Moreira, T. D. C., Freese, L., Ferigolo, M., & Barros, H. M. T. (2008) · Estudos de Psicologia (Natal) · doi:10.1590/s1413-294x2008000200005 · Cited by 13
Liu, Y., Richardson, J. R., Tran, T. P., Al‐Muhtasib, N., Xie, T., Yenugonda, V. M., Sexton, H. G., Rezvani, A. H., Levin, E. D., Sahibzada, N., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4000374 · Cited by 13
Wang, C., Huang, P., Shen, Z., Qian, W. P., Wang, S., Jiaerken, Y., Luo, X., Li, K., Zeng, Q., Zhou, C., et al. (2020) · Addiction Biology · doi:10.1111/adb.12919 · Cited by 13
Overcoming barriers to disseminate effective smoking cessation treatments globally
Patwardhan, S., & Rose, J. E. (2020) · Drugs and Alcohol Today · doi:10.1108/dat-01-2020-0001 · Cited by 14
Pharmacologic Agents for Tobacco Dependence Treatment: 2011 Update
Hays, J. T., McFadden, D. D., & Ebbert, J. O. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0211-2 · Cited by 13
Madsen, H. B., Koghar, H. S., Pooters, T., Massalas, J. S., Drago, J., & Lawrence, A. J. (2014) · Addiction Biology · doi:10.1111/adb.12148 · Cited by 15
The safety of treatments for tobacco use disorder
Little, M. A., & Ebbert, J. O. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1131817 · Cited by 16
Christensen, N. L., Løkke, A., Dalton, S. O., Christensen, J., & Rasmussen, T. R. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.025 · Cited by 13
DiPalma, D. T., Rezvani, A. H., Willette, B. K. A., Wells, C., Slade, S. K., Hall, B. J., & Levin, E. D. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.11.002 · Cited by 13
Abnormal white matter tracts of insula in smokers
Wang, C., Wang, S., Huang, P., Shen, Z., Qian, W. P., Luo, X., Li, K., Zeng, Q., Gu, Q., Yu, H., et al. (2020) · Brain Imaging and Behavior · doi:10.1007/s11682-020-00389-1 · Cited by 13
Treatment of mild chronic obstructive pulmonary disease
Sin, D. D. (2008) · International Journal of COPD · doi:10.2147/copd.s3483 · Cited by 13
S -Adenosyl- l -Methionine (SAMe) for Smoking Abstinence: A Randomized Clinical Trial
Sood, A., Prasad, K., Croghan, I. T., Schroeder, D. R., Ehlers, S. L., & Ebbert, J. O. (2012) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2011.0462 · Cited by 13
Acute Hepatic Injury Associated with Varenicline in a Patient with Underlying Liver Disease
Franck, A. J., & Sliter, L. R. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m131 · Cited by 13
Kanaoka, Y., Koga, M., Sugiyama, K., Ohishi, K., Kataoka, Y., & Yamauchi, A. (2017) · Toxicology · doi:10.1016/j.tox.2017.02.006 · Cited by 13
Therapeutic options and challenges for substances of abuse
Gardner, T. J., & Kosten, T. R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/tgardner · Cited by 13
The place of varenicline in smoking cessation treatment
Aveyard, P. N. (2008) · Thorax · doi:10.1136/thx.2008.096081 · Cited by 13
Budgetary Impact of Varenicline in Smoking Cessation in the United Kingdom
Taylor, D. C. A., Chu, P., Rosen, V. M., Baker, C. L., & Thompson, D. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00395.x · Cited by 12
Roberts, W., Shi, J. M., Tetrault, J. M., & McKee, S. A. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000392 · Cited by 12
Xiao, D., Kotler, M. L., Kang, J., & Wang, C. (2019) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000547 · Cited by 12
Precision nicotine metabolism-informed care for smoking cessation in Crohn’s disease: A pilot study
Scoville, E., Tindle, H. A., Wells, Q. S., Peyton, S. C., Gurwara, S., Pointer, S. O., Horst, S., Schwartz, D. A., Adams, D. W., Freiberg, M. S., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230656 · Cited by 12
Mishra, A., Maiti, R., Mishra, B. R., & Jena, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105478 · Cited by 14
Factors Associated With Smoking Cessation Attempts in Lung Cancer Screening
Thomas, N. A., Ward, R. C., Tanner, N. T., Rojewski, A. M., Toll, B. A., Gebregziabher, M., & Silvestri, G. A. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.08.2239 · Cited by 13
Goeders, N. E., Cohen, A., Fox, B. S., Azar, M. R., George, O., & Koob, G. F. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2682-4 · Cited by 12
Pharmacological Validation of Candidate Causal Sleep Genes Identified in an N2 Cross
Brunner, J. I., Gotter, A. L., Millstein, J., Garson, S. L., Binns, J., Fox, S. V., Savitz, A. T., Yang, H. S., Fitzpatrick, K., Zhou, L., et al. (2011) · Journal of Neurogenetics · doi:10.3109/01677063.2011.628426 · Cited by 12
Perioperative Smoking Cessation
de Hoyos, A., Southard, C., & DeCamp, M. M. (2011) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2011.09.006 · Cited by 13
Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation
Dunn, K. E., Marcus, T. F., Kim, C., Schroeder, J. R., Vandrey, R. G., & Umbricht, A. (2015) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntv236 · Cited by 12
Maggio, S. E., Saunders, M. A., Baxter, T. A., Nixon, K., Prendergast, M., Zheng, G., Crooks, P. A., Dwoskin, L. P., Slack, R. D., Newman, A. H., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4853-4 · Cited by 12
Fletcher, P. J., Li, Z., Silenieks, L. B., MacMillan, C., DeLannoy, I., & Higgins, G. A. (2018) · Addiction Biology · doi:10.1111/adb.12602 · Cited by 12
Zawertailo, L. A., Mansoursadeghi-Gilan, T., Zhang, H., Hussain, S., Foll, B. L., & Selby, P. L. (2018) · JMIR Research Protocols · doi:10.2196/10826 · Cited by 12
Preclinical and clinical research on the discriminative stimulus effects of nicotine
Shoaib, M. C., & Perkins, K. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108063 · Cited by 12
Global research trends and publications of insomnia: A bibliometric analysis
Jallow, A. W., Wang, M.-H., & Ho, Y. (2020) · Collnet Journal of Scientometrics and Information Management · doi:10.1080/09737766.2021.1906184 · Cited by 12
Tønnesen, P., Lawrence, D., & Tonstad, S. (2022) · Tobacco Induced Diseases · doi:10.18332/tid/146567 · Cited by 12
Update in Addiction Medicine for the Generalist
Gordon, A. J., Sullivan, L. E., Alford, D. P., Arnsten, J. H., Gourevitch, M. N., Kertesz, S. G., Kunins, H. V., Merrill, J. O., Samet, J. H., & Fiellin, D. A. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0133-4 · Cited by 12
Pharmacological treatments for tobacco dependence
Fagerström, K. O., & Jimenez-Ruiz, C. A. (2008) · European Respiratory Review · doi:10.1183/09059180.00011004 · Cited by 12
Approach to chronic obstructive pulmonary disease in primary care.
Todd, D. C., McIvor, A., Pugsley, S. O., & Cox, G. (2008) · PubMed Central · Cited by 12
Varenicline: For smoking cessation
Rao, J., & Shankar, P. (1970) · Kathmandu University Medical Journal · doi:10.3126/kumj.v7i2.2714 · Cited by 12
Wilcox, C. E., Claus, E. D., Calhoun, V. D., Rachakonda, S., Littlewood, R. A., Mickey, J., Arenella, P. B., Goodreau, N., & Hutchison, K. E. (2017) · Addiction Biology · doi:10.1111/adb.12498 · Cited by 12
Bohadana, A., Freier‐Dror, Y., Peles, V., Babai, P., & Izbicki, G. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.11.021 · Cited by 12
Advances in the management of chronic obstructive pulmonary disease
Meinke, L. E., Chitkara, R. K., & Krishna, G. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.1.23 · Cited by 12
Trials that Matter: Varenicline: A Designer Drug to Help Smokers Quit
Schroeder, S. A., & Sox, H. C. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00013 · Cited by 12
Improving efficiency of initial tests for efficacy in smoking cessation drug discovery
Perkins, K. A. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.951632 · Cited by 11
Effectiveness of Varenicline as an Aid to Smoking Cessation in Primary Care: An Observational Study
Andreas, S., Chenot, J., Diebold, R., Peachey, S., & Mann, K. F. (2012) · European Addiction Research · doi:10.1159/000341638 · Cited by 11
Tobacco Treatment and Prevention: What Works and Why
Goodfellow, L. T., & Waugh, J. B. (2009) · Respiratory Care · doi:10.4187/respcare.09541082 · Cited by 11
Kim, N., McCarthy, D. E., Piper, M. E., & Baker, T. B. (2020) · Addiction · doi:10.1111/add.15248 · Cited by 11
Effect of Extending the Duration of Prequit Treatment With Varenicline on Smoking Abstinence
Hawk, L. W., Tiffany, S. T., Colder, C. R., Ashare, R. L., Wray, J. M., Tyndale, R. F., Brandon, T. H., & Mahoney, M. C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.41731 · Cited by 11
Translational research in addiction: Toward a framework for the development of novel therapeutics
Paterson, N. E. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.12.017 · Cited by 12
Mainar, A. S., Artieda, R. N., Díaz‐Cerezo, S., Sánchez, B. M., & de Burgoa, V. S. (2011) · Atención Primaria · doi:10.1016/j.aprim.2010.09.010 · Cited by 11
Rehring, T. F., Stolcpart, R. S., & Hollis, H. W. (2008) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.12.033 · Cited by 11
Huang, Y., Li, W., Li, Y., Jiang, Y. Z., & Wu, Y. (2012) · Journal of Public Health · doi:10.1007/s10389-011-0476-5 · Cited by 12
Hughes, J. R. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.10.020 · Cited by 11
Bozinoff, N., & Foll, B. L. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1507736 · Cited by 11
Role of CYP2B6 pharmacogenomics in bupropion-mediated smoking cessation
Tran, A. X. V., COOPERDEHOFF, R., & Gupta, S. V. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12783 · Cited by 12
Khariwala, S. S., Rubin, N., Stepanov, I. S., Nollen, N. L., Ahluwalia, J. S., Nelson, H. H., & Hatsukami, D. K. (2019) · Head & Neck · doi:10.1002/hed.25708 · Cited by 11
Metadata
- Authors
- Gonzales, D.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Gonzales, David
- ORCID
- Gonzales, David
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-07-05
- Volume
- 296
- Issue
- 1
- Pages
- 47
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2107200746
- Cited by
- 1,361
- References
- 29
- Citations by year
- 2026: 32 · 2025: 21 · 2024: 25 · 2023: 25 · 2022: 34 · 2021: 26 · 2020: 52 · 2019: 49 · 2018: 41 · 2017: 51 · 2016: 50 · 2015: 70 · 2014: 74 · 2013: 80 · 2012: 94
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Oregon Health and Science University
- Cardinal Health
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- varenicline, bupropion sustained release, smoking cessation, α4β2 nicotinic acetylcholine receptor, partial agonists, nicotine dependence, continuous abstinence, exhaled carbon monoxide, brief counseling, nicotine replacement therapy, drug safety, adverse events, relapse, nicotine withdrawal symptoms, nicotine self-administration
- MeSH terms
- Varenicline, Adult, Benzazepines, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Receptors, Nicotinic, Smoking Cessation, Bupropion, Nicotinic Agonists, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
